Literature DB >> 9395287

Targeted therapy of cancer with recombinant immunotoxins.

I Pastan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9395287     DOI： 10.1016/s0304-419x(97)00021-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


× No keyword cloud information.
  14 in total

1.  Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.

Authors:  Y Tsutsumi; M Onda; S Nagata; B Lee; R J Kreitman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 2.  Preparation of recombinant RNase single-chain antibody fusion proteins.

Authors:  Dianne L Newton; Susanna M Rybak
Journal:  Mol Biotechnol       Date:  2002-01       Impact factor: 2.695

Review 3.  Recent trends and advances in microbe-based drug delivery systems.

Authors:  Pravin Shende; Vasavi Basarkar
Journal:  Daru       Date:  2019-08-02       Impact factor: 3.117

Review 4.  Bacteria in cancer therapy: a novel experimental strategy.

Authors:  S Patyar; R Joshi; D S Prasad Byrav; A Prakash; B Medhi; B K Das
Journal:  J Biomed Sci       Date:  2010-03-23       Impact factor: 8.410

5.  Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.

Authors:  Galit Denkberg; Cyril J Cohen; Avital Lev; Patrick Chames; Hennie R Hoogenboom; Yoram Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

6.  Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gerald E Archer; Mitchel S Berger; R Edward Coleman; Allan H Friedman; Henry S Friedman; Kim Greer; James E Herndon; Sandeep Kunwar; Roger E McLendon; Alison Paolino; Neil A Petry; James M Provenzale; David A Reardon; Terence Z Wong; Michael R Zalutsky; Ira Pastan; Darell D Bigner
Journal:  Neuro Oncol       Date:  2008-04-10       Impact factor: 12.300

7.  Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo.

Authors:  Avital Lev; Roy Noy; Kfir Oved; Hila Novak; Dina Segal; Peter Walden; Dietmar Zehn; Yoram Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-07       Impact factor: 11.205

8.  Cytotoxic agents directed to peptide hormone receptors: defining the requirements for a successful drug.

Authors:  G Czerwinski; N I Tarasova; C J Michejda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

9.  Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors.

Authors:  John H Sampson; Gamal Akabani; Gary E Archer; Darell D Bigner; Mitchel S Berger; Allan H Friedman; Henry S Friedman; James E Herndon; Sandeep Kunwar; Steve Marcus; Roger E McLendon; Alison Paolino; Kara Penne; James Provenzale; Jennifer Quinn; David A Reardon; Jeremy Rich; Timothy Stenzel; Sandra Tourt-Uhlig; Carol Wikstrand; Terence Wong; Roger Williams; Fan Yuan; Michael R Zalutsky; Ira Pastan
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

10.  Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.

Authors:  Malka Epel; Irit Carmi; Sharon Soueid-Baumgarten; SangKon Oh; Tapan Bera; Ira Pastan; Jay Berzofsky; Yoram Reiter
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 6.688
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.